{"title":"对《柳叶刀呼吸医学》的更正 2020; 8: 696-708","authors":"","doi":"10.1016/s2213-2600(24)00326-6","DOIUrl":null,"url":null,"abstract":"<em>Moll M, Sakornsakolpat P, Shrine N, et al. Chronic obstructive pulmonary disease and related phenotypes: polygenic risk scores in population-based and case-control cohorts.</em> Lancet Respir Med <em>2020; <strong>8:</strong> 696–708</em>—In this Article, a subset of participants from the SPIROMICS cohort were included in the study who were later found to have not provided consent for genetics or to have withdrawn consent for genetics. SPIROMICS I enrolled participants from 2010 to 2016 and performed up to three follow-up visits up to 2016. During SPIROMICS I, the consent form included several questions, including one on genetics. At each follow-up visit, the consent form was repeated and blood was drawn. This process yielded a complex set of consent flags and biospecimens across up to four visits. Unfortunately, the consent flags extracted from consent form questions were not properly reviewed before the isolation of DNA from the stored blood. Therefore, in 2016, some participants who did not consent for genetics, or who had withdrawn consent for genetics, had DNA isolated from blood and were included in the genome-wide association study. To correct the use of SPIROMICS data in this Article, the individuals who did not provide or who withdrew consent (11 controls and 15 cases) were removed and all analyses involving SPIROMICS data were repeated. In figure 2, the odds ratio (OR) for the association of combined polygenic risk score with chronic obstructive pulmonary disease (COPD) was corrected to 2·15 (95% CI 1·88–2·46) for the SPIROMICS non-Hispanic white (NHW) cohort, to 1·82 (1·74–1·89) for the overall fixed-effect model for European cohorts, and to 1·84 (1·60–2·11) for the overall random-effects model for European cohorts. In figure 3A, the ORs for COPD in European cohorts were corrected. In figure 4, the areas under the curve for predicting COPD in the SPIROMICS NHW cohort were corrected. The appendix has also been corrected. None of the findings changed significantly, and the conclusions of the study are unaffected. These corrections have been made to the online version as of Oct 29, 2024.","PeriodicalId":51307,"journal":{"name":"Lancet Respiratory Medicine","volume":"130 1","pages":""},"PeriodicalIF":38.7000,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Correction to Lancet Respir Med 2020; 8: 696–708\",\"authors\":\"\",\"doi\":\"10.1016/s2213-2600(24)00326-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<em>Moll M, Sakornsakolpat P, Shrine N, et al. Chronic obstructive pulmonary disease and related phenotypes: polygenic risk scores in population-based and case-control cohorts.</em> Lancet Respir Med <em>2020; <strong>8:</strong> 696–708</em>—In this Article, a subset of participants from the SPIROMICS cohort were included in the study who were later found to have not provided consent for genetics or to have withdrawn consent for genetics. SPIROMICS I enrolled participants from 2010 to 2016 and performed up to three follow-up visits up to 2016. During SPIROMICS I, the consent form included several questions, including one on genetics. At each follow-up visit, the consent form was repeated and blood was drawn. This process yielded a complex set of consent flags and biospecimens across up to four visits. Unfortunately, the consent flags extracted from consent form questions were not properly reviewed before the isolation of DNA from the stored blood. Therefore, in 2016, some participants who did not consent for genetics, or who had withdrawn consent for genetics, had DNA isolated from blood and were included in the genome-wide association study. To correct the use of SPIROMICS data in this Article, the individuals who did not provide or who withdrew consent (11 controls and 15 cases) were removed and all analyses involving SPIROMICS data were repeated. In figure 2, the odds ratio (OR) for the association of combined polygenic risk score with chronic obstructive pulmonary disease (COPD) was corrected to 2·15 (95% CI 1·88–2·46) for the SPIROMICS non-Hispanic white (NHW) cohort, to 1·82 (1·74–1·89) for the overall fixed-effect model for European cohorts, and to 1·84 (1·60–2·11) for the overall random-effects model for European cohorts. In figure 3A, the ORs for COPD in European cohorts were corrected. In figure 4, the areas under the curve for predicting COPD in the SPIROMICS NHW cohort were corrected. The appendix has also been corrected. None of the findings changed significantly, and the conclusions of the study are unaffected. These corrections have been made to the online version as of Oct 29, 2024.\",\"PeriodicalId\":51307,\"journal\":{\"name\":\"Lancet Respiratory Medicine\",\"volume\":\"130 1\",\"pages\":\"\"},\"PeriodicalIF\":38.7000,\"publicationDate\":\"2024-10-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Lancet Respiratory Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/s2213-2600(24)00326-6\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CRITICAL CARE MEDICINE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lancet Respiratory Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/s2213-2600(24)00326-6","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}
引用次数: 0
摘要
Moll M, Sakornsakolpat P, Shrine N, et al. 慢性阻塞性肺病及相关表型:基于人群和病例对照队列的多基因风险评分。Lancet Respir Med 2020; 8: 696-708-在这篇文章中,SPIROMICS队列中的一部分参与者被纳入了研究,但后来发现他们没有提供遗传学同意书或撤回了遗传学同意书。SPIROMICS I在2010年至2016年期间招募了参与者,并在2016年之前进行了最多三次随访。在 SPIROMICS I 期间,同意书包括几个问题,其中一个是关于遗传学的问题。每次随访时,都要重复填写同意书并抽血。这一过程产生了一组复杂的同意标记和生物样本,涉及多达四次就诊。遗憾的是,在从储存的血液中分离 DNA 之前,没有对从同意书问题中提取的同意标志进行适当审查。因此,2016 年,一些未同意遗传学研究或已撤销遗传学研究同意的参与者从血液中分离出了 DNA,并被纳入了全基因组关联研究。为了纠正本文对 SPIROMICS 数据的使用,删除了未提供同意书或撤回同意书的个体(11 例对照和 15 例病例),并重复了所有涉及 SPIROMICS 数据的分析。在图2中,SPIROMICS非西班牙裔白人(NHW)队列的综合多基因风险评分与慢性阻塞性肺病(COPD)相关性的比值比(OR)被校正为2-15(95% CI 1-88-2-46),欧洲队列的总体固定效应模型的比值比(OR)被校正为1-82(1-74-1-89),欧洲队列的总体随机效应模型的比值比(OR)被校正为1-84(1-60-2-11)。在图 3A 中,对欧洲队列中慢性阻塞性肺病的 ORs 进行了校正。在图 4 中,对 SPIROMICS NHW 队列中预测慢性阻塞性肺病的曲线下面积进行了更正。附录也做了更正。所有结果均无重大变化,研究结论不受影响。这些更正已在 2024 年 10 月 29 日的在线版本中做出。
Moll M, Sakornsakolpat P, Shrine N, et al. Chronic obstructive pulmonary disease and related phenotypes: polygenic risk scores in population-based and case-control cohorts. Lancet Respir Med 2020; 8: 696–708—In this Article, a subset of participants from the SPIROMICS cohort were included in the study who were later found to have not provided consent for genetics or to have withdrawn consent for genetics. SPIROMICS I enrolled participants from 2010 to 2016 and performed up to three follow-up visits up to 2016. During SPIROMICS I, the consent form included several questions, including one on genetics. At each follow-up visit, the consent form was repeated and blood was drawn. This process yielded a complex set of consent flags and biospecimens across up to four visits. Unfortunately, the consent flags extracted from consent form questions were not properly reviewed before the isolation of DNA from the stored blood. Therefore, in 2016, some participants who did not consent for genetics, or who had withdrawn consent for genetics, had DNA isolated from blood and were included in the genome-wide association study. To correct the use of SPIROMICS data in this Article, the individuals who did not provide or who withdrew consent (11 controls and 15 cases) were removed and all analyses involving SPIROMICS data were repeated. In figure 2, the odds ratio (OR) for the association of combined polygenic risk score with chronic obstructive pulmonary disease (COPD) was corrected to 2·15 (95% CI 1·88–2·46) for the SPIROMICS non-Hispanic white (NHW) cohort, to 1·82 (1·74–1·89) for the overall fixed-effect model for European cohorts, and to 1·84 (1·60–2·11) for the overall random-effects model for European cohorts. In figure 3A, the ORs for COPD in European cohorts were corrected. In figure 4, the areas under the curve for predicting COPD in the SPIROMICS NHW cohort were corrected. The appendix has also been corrected. None of the findings changed significantly, and the conclusions of the study are unaffected. These corrections have been made to the online version as of Oct 29, 2024.
期刊介绍:
The Lancet Respiratory Medicine is a renowned journal specializing in respiratory medicine and critical care. Our publication features original research that aims to advocate for change or shed light on clinical practices in the field. Additionally, we provide informative reviews on various topics related to respiratory medicine and critical care, ensuring a comprehensive coverage of the subject.
The journal covers a wide range of topics including but not limited to asthma, acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), tobacco control, intensive care medicine, lung cancer, cystic fibrosis, pneumonia, sarcoidosis, sepsis, mesothelioma, sleep medicine, thoracic and reconstructive surgery, tuberculosis, palliative medicine, influenza, pulmonary hypertension, pulmonary vascular disease, and respiratory infections. By encompassing such a broad spectrum of subjects, we strive to address the diverse needs and interests of our readership.